Ono obtains exclusive global rights for the development and commercialization of sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV), a rare and potentially life-threatening hematologic disease.
Ionis is also eligible to earn royalties in the mid-teen percentage range on annual net sales of sapablursen.
Comment(0)
Reason For Report